Skip to content

US · INTS · BIOTECHNOLOGY

Intensity Therapeutics, Inc. (INTS) intrinsic value and stock valuation

$2.48as of 2026-11-21 · Mkt cap 11.35M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Intensity Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values INTS with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from INTS’s statements →

Intensity Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Shelton, CT 06484-4779 intensitytherapeutics.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$0.00
20192025
Net income
-$-11.61M
20192025
Free cash flow
-$-9.23M
20192025
Total equity
$11.9M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-11.97M-$-16.59M-$-8.32M-$-7.55M-$-8.01M
Net income-$-11.61M-$-16.27M-$-10.54M-$-7.58M-$-7.9M
EPSd-$-856.19K-$-29.05M-$-31M-$-54.14M-$-56.43M
Operating cash flow-$-9.23M-$-15.22M-$-7.21M-$-5.48M-$-6.83M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-9.23M-$-15.22M-$-7.21M-$-5.48M-$-6.83M
Total assets$14.1M$4.78M$17.3M$1.76M$5.22M
Total debt$110K$140K$160K$4.49M$2.34M
Net debt-$-11.81M-$-2.45M-$-8.4M$3.18M-$-2.2M
Total equity$11.9M$2.92M$13.2M-$-15.1M-$-8.68M
Cash and short-term investments$11.9M$2.59M$14.8M$1.31M$4.54M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$30K$0.00$150K$0.00$0.00
Gross profit-$-30K$0.00-$-150K$0.00$0.00
Research and development expenses$6.79M$10.5M$4.79M$5.13M$5.86M
Selling, general and administrative expenses$5.19M$6.09M$3.39M$2.42M$2.14M
Other expenses$0.00$0.00$0.00$0.00$20K
Operating expenses$12M$16.6M$8.17M$7.55M$8.01M
Cost and expenses$12M$16.6M$8.32M$7.55M$8.01M
Interest income$180K$310K$320K$0.00$0.00
Interest expense$0.00$0.00$300K$80K$20K
Depreciation and amortization$0.00$0.00$150K$180K$0.00
Ebitda-$-11.61M-$-16.27M-$-10.09M-$-7.32M-$-7.88M
Operating income-$-11.97M-$-16.59M-$-8.32M-$-7.55M-$-8.01M
Total other income/expenses, net$370K$320K-$-2.22M-$-30K$120K
Income before tax-$-11.61M-$-16.27M-$-10.54M-$-7.58M-$-7.9M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-11.61M-$-16.27M-$-10.54M-$-7.58M-$-7.9M
Weighted average shares outstanding$13.6M$560K$310K$140K$140K
Weighted average diluted shares outstanding$13.6M$560K$340K$140K$140K
Balance sheet
20252024202320222021
Cash and short-term investments$11.9M$2.59M$14.8M$1.31M$4.54M
Net receivables$0.00$0.00$0.00$60K$50K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$12.7M$3.36M$15.5M$1.45M$4.73M
Property, plant and equipment, net$100K$120K$150K$140K$320K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$1.39M$1.42M$1.83M$310K$490K
Total assets$14.1M$4.78M$17.3M$1.76M$5.22M
Accounts payable$580K$1.22M$3.05M$600K$170K
Short-term debt$30K$30K$20K$4.49M$2.2M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$2.15M$1.75M$3.96M$6.82M$3.72M
Long-term debt$80K$110K$140K$0.00$140K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$80K$110K$170K$10M$10.2M
Capital lease obligations$30K$140K$160K$140K$330K
Total liabilities$2.23M$1.86M$4.13M$16.9M$13.9M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-78.39M-$-66.78M-$-50.52M-$-38.65M-$-31.07M
Accumulated other comprehensive income (loss)$0.00$0.00-$-17.3M$0.00$0.00
Total equity$11.9M$2.92M$13.2M-$-15.1M-$-8.68M
Total investments$0.00$0.00$6.22M$0.00$0.00
Total debt$110K$140K$160K$4.49M$2.34M
Net debt-$-11.81M-$-2.45M-$-8.4M$3.18M-$-2.2M
Cash flow statement
20252024202320222021
Net income-$-11.61M-$-16.27M-$-10.54M-$-7.58M-$-7.9M
Depreciation and amortization$0.00$0.00$0.00$180K$0.00
Stock-based compensation$2M$3.07M$1.4M$1.17M$720K
Change in working capital$350K-$-2.1M-$-630K$760K$180K
Accounts receivable$0.00$0.00$0.00$0.00$20K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$360K-$-2.27M$1.63M$430K-$-50K
Net cash provided by operating activities-$-9.23M-$-15.22M-$-7.21M-$-5.48M-$-6.83M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$6.35M-$-6.02M$0.00$0.00
Common stock issued$18.6M$3.23M$22.4M$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$18.6M$2.9M$20.5M$2.25M$2.05M
Net change in cash$9.33M-$-5.97M$7.24M-$-3.23M-$-4.78M
Cash at end of period$11.9M$2.59M$8.56M$1.31M$4.54M
Operating cash flow-$-9.23M-$-15.22M-$-7.21M-$-5.48M-$-6.83M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-9.23M-$-15.22M-$-7.21M-$-5.48M-$-6.83M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Intensity Therapeutics, Inc.

        Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid tumor cancers. The company's primary experimental compound, INT230-6, is presently undergoing Phase 2 clinical trials. This investigational drug targets a range of difficult-to-treat solid tumors, including those affecting the pancreas, colon, bile duct, as well as squamous cell, sarcoma, breast, and liver cancers. Intensity Therapeutics has formed strategic collaborations with major pharmaceutical companies and research institutions: A partnership with Merck Sharpe & Dohme Corp. focuses on evaluating INT230-6 in conjunction with Keytruda for advanced pancreatic, colon, squamous cell, and bile duct malignancies. Another collaboration with Bristol-Myers Squibb Company is dedicated to studying INT230-6 combined with Yervoy in patients suffering from advanced liver, breast, and sarcoma cancers. Furthermore, the company is working with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research on a randomized controlled Phase II neoadjuvant study of INT230-6 for women diagnosed with early-stage breast cancer. Established in 2012, Intensity Therapeutics maintains its corporate headquarters in Westport, Connecticut.

        CEO
        Lewis H. Bender
        Employees
        16
        Beta
        3.05

        Explore

        Frequently asked questions

        What is the intrinsic value of Intensity Therapeutics, Inc. (INTS)?

        InvestorsCraft does not currently publish an intrinsic value for INTS. How the IC value is calculated.

        Is INTS undervalued?

        InvestorsCraft does not publish an undervaluation signal for INTS at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.